Augmedix (AUGX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AUGX Stock Forecast

Augmedix stock forecast is as follows: an average price target of $2.67 (represents a 13.62% upside from AUGX’s last price of $2.35) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

AUGX Price Target

The average price target for Augmedix (AUGX) is $2.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.50 to $1.50. This represents a potential 13.62% upside from AUGX's last price of $2.35.

AUGX Analyst Ratings

Hold

According to 5 Wall Street analysts, Augmedix's rating consensus is 'Hold'. The analyst rating breakdown for AUGX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Augmedix Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 14, 2024	Brooks O'Neil	Loop Capital Markets	-	-	204.35%	48.94%
May 14, 2024	Yuan Zhi	B.Riley Financial	-	-	28.21%	27.66%
May 14, 2024	Elizabeth Anderson	Evercore ISI	-	-	-35.90%	-36.17%
Apr 09, 2024	Elizabeth Anderson	Evercore ISI	-	-	24.38%	112.77%
Apr 03, 2024	Yuan Zhi	B.Riley Financial	-	-	36.82%	134.04%
Mar 19, 2024	Elizabeth Anderson	Evercore ISI	-	-	13.64%	91.49%

Row per page

Go to

The latest Augmedix stock forecast, released on May 14, 2024 by Brooks O'Neil from Loop Capital Markets, set a price target of $3.50, which represents a 204.35% increase from the stock price at the time of the forecast ($1.15), and a 48.94% increase from AUGX last price ($2.35).

Augmedix Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	6
Avg Price Target	-	-	$3.83
Last Closing Price	$2.35	$2.35	$2.35
Upside/Downside	-100.00%	-100.00%	62.98%

In the current month, the average price target of Augmedix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Augmedix's last price of $2.35. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 19, 2024	B. Riley		Neutral	Downgrade
Jul 19, 2024	William Blair		Market Perform	Downgrade
Jun 04, 2024	Lake Street	Buy	Buy	Hold
May 14, 2024	Lake Street	Buy	Buy	Hold
Apr 09, 2024	Evercore ISI		Outperform	Upgrade
Apr 26, 2022	Zacks Investment Research		Hold	Upgrade

Row per page

Go to

Augmedix's last stock rating was published by B. Riley on Jul 19, 2024. The company Downgrade its AUGX rating from "null" to "Neutral".

Augmedix Financial Forecast

Augmedix Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	-	-	-	-	$12.68M	$11.77M	-	$9.63M	$8.75M	$7.86M	$7.33M	$6.99M	$6.58M	$5.63M	$5.17M
Avg Forecast	$17.70M	$16.79M	$15.51M	$14.59M	$12.89M	$12.96M	$13.64M	$13.36M	$12.46M	$11.43M	$10.37M	$9.39M	$8.57M	$7.76M	$7.33M	$6.91M	$6.40M	$5.61M	$5.18M
High Forecast	$17.70M	$16.79M	$15.51M	$14.59M	$12.89M	$13.07M	$13.64M	$13.36M	$12.46M	$11.43M	$10.37M	$9.39M	$8.57M	$7.76M	$7.33M	$6.91M	$6.40M	$5.61M	$5.18M
Low Forecast	$17.70M	$16.79M	$15.51M	$14.59M	$12.89M	$12.83M	$13.64M	$13.36M	$12.46M	$11.43M	$10.37M	$9.39M	$8.57M	$7.76M	$7.33M	$6.91M	$6.40M	$5.61M	$5.18M
# Analysts	1	1	1	1	1	2	1	1	3	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	1.02%	1.03%	-	1.03%	1.02%	1.01%	1.00%	1.01%	1.03%	1.00%	1.00%

Augmedix's average Quarter revenue forecast for Mar 24 based on 1 analysts is $13.36M, with a low forecast of $13.36M, and a high forecast of $13.36M. AUGX's average Quarter revenue forecast represents a 5.38% increase compared to the company's last Quarter revenue of $12.68M (Dec 23).

Augmedix EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	2	1	1	3	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	$-4.04M	$-4.40M	-	$-5.09M	$-5.44M	$-5.46M	$-6.05M	$-5.45M	$-5.45M	$-2.11M	$-3.87M
Avg Forecast	$-13.30M	$-12.62M	$-11.65M	$-10.96M	$-9.68M	$-9.74M	$-10.25M	$-10.04M	$-9.36M	$-8.59M	$-7.79M	$-7.06M	$-6.44M	$-5.83M	$-5.51M	$-4.28M	$-4.81M	$-1.90M	$-3.89M
High Forecast	$-13.30M	$-12.62M	$-11.65M	$-10.96M	$-9.68M	$-9.64M	$-10.25M	$-10.04M	$-9.36M	$-8.59M	$-7.79M	$-7.06M	$-6.44M	$-5.83M	$-5.51M	$-3.43M	$-4.81M	$-1.52M	$-3.89M
Low Forecast	$-13.30M	$-12.62M	$-11.65M	$-10.96M	$-9.68M	$-9.83M	$-10.25M	$-10.04M	$-9.36M	$-8.59M	$-7.79M	$-7.06M	$-6.44M	$-5.83M	$-5.51M	$-5.14M	$-4.81M	$-2.28M	$-3.89M
Surprise %	-	-	-	-	-	-	-	-	0.43%	0.51%	-	0.72%	0.85%	0.94%	1.10%	1.27%	1.13%	1.11%	0.99%

undefined analysts predict AUGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Augmedix's previous annual EBITDA (undefined) of $NaN.

Augmedix Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	2	1	1	3	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	$-4.49M	$-4.41M	-	$-5.27M	$-5.76M	$-5.52M	$-8.84M	$-6.43M	$-6.08M	$-2.86M	$-4.64M
Avg Forecast	$-4.80M	$-5.87M	$-6.41M	$-6.94M	$-7.47M	$-7.21M	$-7.12M	$-6.94M	$-5.21M	$-6.14M	$-6.94M	$-8.01M	$-8.34M	$-9.21M	$-8.41M	$-5.09M	$-8.28M	$-2.57M	$-10.14M
High Forecast	$-4.80M	$-5.87M	$-6.41M	$-6.94M	$-7.47M	$-7.21M	$-7.12M	$-6.94M	$-5.21M	$-6.14M	$-6.94M	$-8.01M	$-8.34M	$-9.21M	$-8.41M	$-4.07M	$-8.28M	$-2.06M	$-10.14M
Low Forecast	$-4.80M	$-5.87M	$-6.41M	$-6.94M	$-7.47M	$-7.21M	$-7.12M	$-6.94M	$-5.21M	$-6.14M	$-6.94M	$-8.01M	$-8.34M	$-9.21M	$-8.41M	$-6.11M	$-8.28M	$-3.09M	$-10.14M
Surprise %	-	-	-	-	-	-	-	-	0.86%	0.72%	-	0.66%	0.69%	0.60%	1.05%	1.26%	0.73%	1.11%	0.46%

Augmedix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Augmedix SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	2	1	1	3	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	$7.65M	$7.30M	-	$6.77M	$6.88M	$6.44M	$6.60M	$6.28M	$-7.92M	$5.39M	$4.95M
Avg Forecast	$15.74M	$14.94M	$13.79M	$12.98M	$11.46M	$11.52M	$12.13M	$11.89M	$11.08M	$10.16M	$9.23M	$8.35M	$7.62M	$6.90M	$6.52M	$5.38M	$5.69M	$4.86M	$4.61M
High Forecast	$15.74M	$14.94M	$13.79M	$12.98M	$11.46M	$11.63M	$12.13M	$11.89M	$11.08M	$10.16M	$9.23M	$8.35M	$7.62M	$6.90M	$6.52M	$6.46M	$5.69M	$5.83M	$4.61M
Low Forecast	$15.74M	$14.94M	$13.79M	$12.98M	$11.46M	$11.41M	$12.13M	$11.89M	$11.08M	$10.16M	$9.23M	$8.35M	$7.62M	$6.90M	$6.52M	$4.30M	$5.69M	$3.88M	$4.61M
Surprise %	-	-	-	-	-	-	-	-	0.69%	0.72%	-	0.81%	0.90%	0.93%	1.01%	1.17%	-1.39%	1.11%	1.07%

Augmedix's average Quarter SG&A projection for Mar 24 is $11.89M, based on 1 Wall Street analysts, with a range of $11.89M to $11.89M. The forecast indicates a 55.30% rise compared to AUGX last annual SG&A of $7.65M (Dec 23).

Augmedix EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	2	1	1	3	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	$-0.09	$-0.10	-	$-0.14	$-0.15	$-0.15	$-0.24	$-0.17	$-0.16	$-0.11	$-0.17
Avg Forecast	$-0.09	$-0.11	$-0.12	$-0.13	$-0.14	$-0.14	$-0.13	$-0.13	$-0.10	$-0.12	$-0.13	$-0.15	$-0.16	$-0.17	$-0.16	$-0.15	$-0.15	$-0.14	$-0.19
High Forecast	$-0.09	$-0.11	$-0.12	$-0.13	$-0.14	$-0.14	$-0.13	$-0.13	$-0.10	$-0.12	$-0.13	$-0.15	$-0.16	$-0.17	$-0.16	$-0.15	$-0.15	$-0.14	$-0.19
Low Forecast	$-0.09	$-0.11	$-0.12	$-0.13	$-0.14	$-0.14	$-0.13	$-0.13	$-0.10	$-0.12	$-0.13	$-0.15	$-0.16	$-0.17	$-0.16	$-0.15	$-0.15	$-0.14	$-0.19
Surprise %	-	-	-	-	-	-	-	-	0.94%	0.84%	-	0.93%	0.96%	0.87%	1.52%	1.11%	1.03%	0.76%	0.89%

According to undefined Wall Street analysts, Augmedix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUGX previous annual EPS of $NaN (undefined).

Augmedix Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	-	-	4275.00%	Buy
ELEV	Elevation Oncology	-	-	1375.41%	Buy
DRMA	Dermata Therapeutics	-	-	421.74%	Buy
AUGX	Augmedix	-	-	13.62%	Hold
UTRS	Minerva Surgical	-	-	-	Buy

AUGX Forecast FAQ

Is Augmedix a good buy?

No, according to 5 Wall Street analysts, Augmedix (AUGX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of AUGX's total ratings.

What is AUGX's price target?

Augmedix (AUGX) average price target is $2.67 with a range of $1.5 to $3.5, implying a 13.62% from its last price of $2.35. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Augmedix stock go up soon?

According to Wall Street analysts' prediction for AUGX stock, the company can go up by 13.62% (from the last price of $2.35 to the average price target of $2.67), up by 48.94% based on the highest stock price target, and down by -36.17% based on the lowest stock price target.

Can Augmedix stock reach $4?

AUGX's average twelve months analyst stock price target of $2.67 does not support the claim that Augmedix can reach $4 in the near future.

What are Augmedix's analysts' financial forecasts?

Augmedix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $52.84M (high $52.96M, low $52.71M), average EBITDA is $-39.708M (high $-39.612M, low $-39.797M), average net income is $-28.74M (high $-28.74M, low $-28.74M), average SG&A $47M (high $47.11M, low $46.89M), and average EPS is $-0.538 (high $-0.538, low $-0.538). AUGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.59M (high $64.59M, low $64.59M), average EBITDA is $-48.538M (high $-48.538M, low $-48.538M), average net income is $-24.024M (high $-24.024M, low $-24.024M), average SG&A $57.45M (high $57.45M, low $57.45M), and average EPS is $-0.45 (high $-0.45, low $-0.45).

Did the AUGX's actual financial results beat the analysts' financial forecasts?

Based on Augmedix's last annual report (Dec 2023), the company's revenue was $44.86M, beating the average analysts forecast of $43.65M by 2.76%. Apple's EBITDA was $-17.681M, missing the average prediction of $-32.803M by -46.10%. The company's net income was $-19.171M, missing the average estimation of $-26.293M by -27.09%. Apple's SG&A was $29.13M, missing the average forecast of $38.83M by -24.98%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-0.493 by -10.66%. In terms of the last quarterly report (Dec 2023), Augmedix's revenue was $12.68M, beating the average analysts' forecast of $12.46M by 1.77%. The company's EBITDA was $-4.041M, missing the average prediction of $-9.363M by -56.84%. Augmedix's net income was $-4.491M, missing the average estimation of $-5.205M by -13.72%. The company's SG&A was $7.65M, missing the average forecast of $11.08M by -30.95%. Lastly, the company's EPS was $-0.0916, missing the average prediction of $-0.0975 by -6.05%